Cizzle Biotechnology Holdings PLC on Tuesday said that it is using its early-stage lung cancer test technology to detect more cancer types, notably breast cancer.

The London-based diagnostics developer said that it is developing a blood test for the early detection of lung cancer, which uses technology based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. ‘CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer’, Cizzle added.

Further, the company said that new projects have been initiated to evaluate the use of CIZ1B for the detection of other cancers, with an initial focus on breast cancer, which could widen the utility of this cancer biomarker.

Back in July last year, Cizzle announced a collaboration with FairJourney Biologics for the development and supply of proprietary key monoclonal antibodies and other detector proteins. Since then, the company said that it has been able to successfully produce monoclonal reporter antibodies.

Chair Allan Syms said: ‘In its early stage, cancer can be asymptomatic and remain undetected until the disease has advanced, lowering survival rates. Simple, inexpensive, blood tests for early cancer detection can help save lives.

‘The recent progress made in developing these tests at Cizzle Biotechnology, not just for lung cancer, but for a range of other cancers is a significant step forward in our ambitions to provide the right tools to improve cancer patient outcomes,’ Syms added.

Shares in Cizzle Biotechnology were up 4.4% to 1.41 pence each in London on Tuesday midday.

Copyright 2022 Alliance News Limited. All Rights Reserved.